About Vaxonyx
Biotechnology built for impact
Vaxonyx is a biotechnology company focused on developing innovative, accessible, and affordable genetic, vaccine, and immunotherapy solutions powered by AI and molecular biology. Our multidisciplinary expertise spans preclinical R&D, IND-enabling studies, and therapeutic platform development, with a commitment to translating scientific discovery into real-world health impact.
To develop innovative, accessible & affordable platforms
At Vaxonyx, our mission is to develop innovative, accessible, and affordable genetic, vaccine, and immunotherapy platforms using AI and molecular biology to tackle infectious diseases, cancer, and immune disorders. We strive to turn scientific breakthroughs into real-world health solutions for everyone, everywhere.
Lead globally in AI-driven biotechnology
Vaxonyx’s vision is to lead globally in AI-driven biotechnology by creating advanced DNA platforms that revolutionize vaccine and gene therapy development. The company aims to set new standards for precision and effectiveness, making personalized therapies accessible and affordable for all.
Team
We are scientists, engineers, and builders advancing computational immunology and translational biology.
We are building a dynamic and multidisciplinary team under the leadership of Dr. Kempaiah Rayavara, an accomplished scientist and biotech executive with over two decades of experience in molecular biology, infectious diseases, and preclinical research and development.
Kempaiah Rayavara, PhD
Transforming global health with AI-guided genetic, vaccine, and immunotherapy platforms.
Full bio
Kempaiah Rayavara, PhD, is the Founder and President of Vaxonyx. With 20+ years leading interdisciplinary research, he specializes in harnessing artificial intelligence and molecular biology to address infectious diseases, cancer, and immune disorders. He has guided programs from discovery through IND submission and FDA approval, including preclinical GLP safety and efficacy studies in rodent and non-human primate models.
Previously, as Director of Preclinical R&D at Imunon Inc., he led the design and development of a plasmid DNA vaccine, overseeing IND-enabling efficacy, biodistribution, and toxicology studies that resulted in Phase I clinical approval. Earlier, at NIAID/NIH, he contributed to the identification of the malaria parasite gene responsible for the PSAC nutrient acquisition channel. His experience spans drug-mechanism research for tissue repair (Chrysalis BioTherapeutics) and development of models for respiratory viruses (RSV, COVID-19, influenza) at UTMB and Southern Research— playing a key role in establishing COVID-19 models during the pandemic.
He earned his PhD in Biochemistry studying the pharmaceutical potential of nutraceuticals against diet-induced obesity. This broad expertise underpins Vaxonyx’s commitment to rigorous, high-quality solutions that bridge cutting-edge biotechnology with real-world impact worldwide.
